We are live on
!
Find out more
BC
Broadfin Capital Portfolio holdings
AUM
$747M
1-Year Est. Return
100.56%
This Fund
S&P 500
This Quarter
Est. Return
-15.46%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$761M
AUM Growth
+$81M
(+12%)
Cap. Flow
+$243M
Cap. Flow
% of AUM
31.93%
Top 10 Holdings %
Top 10 Hldgs %
59.91%
Holding
63
New
13
Increased
16
Reduced
15
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVRO
NEVRO CORP.
NVRO
|
+$33.1M |
| 2 |
DexCom
DXCM
|
+$19.8M |
| 3 |
Aclaris Therapeutics
ACRS
|
+$19.4M |
| 4 |
ADMS
Adamas Pharmaceuticals
ADMS
|
+$16.7M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
+$16.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CORI
Corium International, Inc.
CORI
|
+$22.5M |
| 2 |
Tandem Diabetes Care
TNDM
|
+$17.1M |
| 3 |
Pacific Biosciences
PACB
|
+$13.5M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$11.8M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$8.04M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Alnylam Pharmaceuticals
ALNY
$35.7B
| – | – |
-62,200
| Closed | -$5.44M |
|
|
AMRN
52
CALL
Amarin Corp
AMRN
$292M
| – | – |
-72,750
| Closed | -$23.7M |
|
53
AngioDynamics
ANGO
$558M
| – | – |
-289,035
| Closed | -$6.28M |
|
54
CALL
Heron Therapeutics
HRTX
$89.1M
| – | – |
-100,000
| Closed | -$3.17M |
|
55
PUT
iShares Russell 2000 ETF
IWM
$82.2B
| – | – |
-400,000
| Closed | -$67.4M |
|
|
56
Pacific Biosciences
PACB
$447M
| – | – |
-2,493,021
| Closed | -$13.5M |
|
57
SCYNEXIS
SCYX
$42.4M
| – | – |
-23,574
| Closed | -$2.26M |
|
|
58
Xenon Pharmaceuticals
XENE
$6.6B
| – | – |
-895,553
| Closed | -$11.8M |
|
|
HZNP
59
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-410,532
| Closed | -$8.04M |
|
|
CORI
60
DELISTED
Corium International, Inc.
CORI
| – | – |
-2,368,557
| Closed | -$22.5M |
|
|
OMED
61
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| – | – |
-200,000
| Closed | -$424K |
|
|
LJPC
62
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
| – | – |
-100,000
| Closed | -$2.01M |
|
Similar funds
CBU
CONA
MP
SC
KGACF
BPWA
TRAM
VMI
Broadfin Capital's Q4 2018 Portfolio in Review
As of Q4 2018, Broadfin Capital held 63 positions worth $761M, up 12% from $680M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Broadfin Capital deployed $243M of net new capital in Q4 2018, opening 13 new positions and adding to 16 existing holdings. Its largest new stake was NEVRO CORP.: 744,415 shares worth $28.9M.
By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 73% a quarter earlier.
On the sell side, the largest reduction was Tandem Diabetes Care, an estimated $17.1M trimmed.
- Broadfin Capital's largest Q4 2018 buy was NEVRO CORP.: 744,415 shares worth $28.9M.
- Broadfin Capital added most to DexCom in Q4 2018, an estimated $19.8M increase.
- Broadfin Capital's biggest Q4 2018 reduction was Tandem Diabetes Care, cutting an estimated $17.1M.
- Broadfin Capital fully exited Corium International, Inc. in Q4 2018, selling an estimated $22.5M.
- Broadfin Capital's ten largest holdings make up 60% of its $761M portfolio in Q4 2018.
- Broadfin Capital opened 13 new positions and closed 13 in Q4 2018.
- Broadfin Capital's portfolio value rose 12% quarter-over-quarter to $761M.
Based on Broadfin Capital's 13F filing for Q4 2018, filed 14 Feb 2019.